drugset / Trial / NCT01436864
A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD
Phase 3
Completed
125 enrolled
Chengdu Kanghong Biotech Co., Ltd.
University of Wisconsin, Madison · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to prove and confirm the efficacy and safety of multiple injections of human recombinant vascular endothelial growth factor receptor-Fc fusion protein (KH902) in patients with choroidal neovascularization due to neovascular age-related macular degeneration by comparing intravitreal injections of KH902 with sham-injections.
Timeline
- Start
- 2011-08
- Primary completion
- 2012-12
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Conbercept | Protein / enzyme biologic | 0.5 mg | Intravitreal |